Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard C. Christopher
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- 0.34
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -17.90
Financials
Revenue
$0.00-100.0%Net Income
$-1.99MEBITDA
$-1.99MFree Cash Flow
$-1.66MEPS (diluted)
$-1.20Shares Outstanding (diluted)
1.65M+1552.5%Operating Expenses
$1.99MCash & Debt
$3.62MRevenue by Segment (annual)
$705.9KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $705.9K | $-11.90M | $-9.90 |
| 2024 | $464.3K | $-5.80M | $-7.05 |
| 2023 | $226.2K | $-6.66M | $-15.15 |
| 2022 | $255.4K | $-7.27M | $-18.60 |
| 2021 | $722.7K | $-4.03M | $-13.80 |
| 2020 | $384.5K | $-3.93M | $-21.30 |
| 2019 | $222.6K | $-4.10M | $-24.30 |
| 2018 | $433.3K | $-6.60M | $-41.85 |
| 2017 | $63.6K | $-1.87M | $-14.25 |
| 2016 | $40.7K | $-1.21M | $-12.45 |
| 2015 | $14.7K | $-1.77M | $-20.10 |
| 2014 | $1.10M | $-1.87M | $-1.09 |
| 2013 | $1.10M | $-343.6K | $-6.30 |
| 2012 | $1.36M | $-251.5K | $-16.35 |
Valuation
LEXXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
23-82.72%Social Signal Score
Mentions (6)
- Newsaccessnewswire.com·26d ago·Negative
…Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 …
View source ↗ - Newsthenewswire.com·28d ago·Negative
…Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, havi…
View source ↗ - Newsthenewswire.com·35d ago·Negative
…25 Australian human study results in a USD$2.6 million cash rebate Kelowna, British Columbia – September 1 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , is pleased to announce that it has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria's wholly-owned Australian subsidiary company, Lexaria (AU) Pty Ltd.
View source ↗ - Newsaccessnewswire.com·43d ago·Negative
…y evidencing DehydraTECH benefits for oral delivery of next generation GLP-1 drugs KELOWNA, BC / ACCESS Newswire / August 24, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that blood plasma pharmacokinetic ("PK") bioanalysis testing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2, the "Study"). The Study examined oral delivery of 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs, amycr…
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know Lexaria Bioscience Corp. (NASDAQ:LEXX) shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd. Here's what investors need to know.
View source ↗ - Newsaccessnewswire.com·54d ago·Negative
Lexaria Enters a Material Transfer Agreement With PegBio KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into a Material Transfer Agreement ("MTA") with Pegbio Co., Ltd ("PegBio") to investigate Lexaria's DehydraTECH technology with a proprietary PegBio molecule under development for the GLP-1 industry. Today's announcement is separate from, and has …
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $-0.90 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jul 13$-1.20 vs $-0.90miss
- Mon, Apr 13$-0.90 vs $-1.05beat
- Tue, Jan 13$-1.05 vs $-1.95beat
- Wed, Nov 26$-2.10 vs $-2.40beat
- Mon, Jul 14$-3.15 vs $-2.25miss
- Mon, Apr 14$-2.25 vs $-2.40beat
Estimates and results for LEXX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LEXX officers and directors.
- Bought
- $255k
- Sold
- $10k
13 trades
1 trade
- Bunka Christopherbought
- Bunka Christopherbought
- Mckechnie William Edwardbought
- Docherty John Martinbought
- Carle Vanessabought
- Christopher Richardbought
- Christopher Richardbought
- Christopher Richardbought
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LEXX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.